Volume 194, number 12: Is Human Herpesvirus-6 DNA in Plasma the Right Marker for Active Infection?
14th Nov 2006, 01:00 GMT
Volume 194, number 12: Is Human Herpesvirus-6 DNA in Plasma the Right Marker for Active Infection? related news:
- Volume 194, number 12: Treatment Benefit on Cerebrospinal Fluid HIV-1 Levels in the Setting of Systemic Virological Suppression and Failure — J Infect Dis Latest Issue
- Volume 194, number 12: Immune-Based Therapy for HIV Infection: Are Acute and Chronic HIV Infection Different Diseases? — J Infect Dis Latest Issue
- Volume 194, number 12: Equal Amounts of Intracellular and Virion-Enclosed Hepatitis C Virus RNA Are Associated with Peripheral-Blood Mononuclear Cells In Vivo — J Infect Dis Latest Issue
- Volume 194, number 12: Blinded Case-Control Study of the Relationship between Human Coronavirus NL63 and Kawasaki Syndrome — J Infect Dis Latest Issue
- Volume 194, number 12: Viral Load, E2 Gene Disruption Status, and Lineage of Human Papillomavirus Type 16 Infection in Cervical Neoplasia — J Infect Dis Latest Issue
- Volume 194, number 12: Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138 — J Infect Dis Latest Issue
- Scientists Explore Function of 'Junk DNA' — PhysOrg.com - latest science and technology news
- Volume 194, number 12: Evaluation of Purified Taenia solium Glycoproteins and Recombinant Antigens in the Serologic Detection of Human and Swine Cysticercosis — J Infect Dis Latest Issue
- Volume 194, number 12: Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand — J Infect Dis Latest Issue
- University of Iowa scientists explore function of 'junk DNA' — EurekAlert! - Biology
Latest news from J Infect Dis Latest Issue:
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine
- Volume 194, number 12: Quantification of Viral Inactivation by Photochemical Treatment with Amotosalen and UV A Light, Using a Novel Polymerase Chain Reaction Inhibition Method with Preamplification
- Volume 194, number 12: Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138
- Volume 194, number 12: Evaluation of Purified Taenia solium Glycoproteins and Recombinant Antigens in the Serologic Detection of Human and Swine Cysticercosis
- Volume 194, number 12: Phase 1 Clinical Trials of the National Institutes of Health Vaccine Research Center HIV/AIDS Candidate Vaccines
- Volume 194, number 12: Is There a Safe Age for Vaccinating Infants with Tetravalent Rhesus-Human Reassortant Rotavirus Vaccine?
- Volume 194, number 12: Reply to Gargiullo et al.
- Volume 194, number 12: Is Panton-Valentine Leukocidin the Major Virulence Determinant in Community-Associated Methicillin-Resistant Staphylococcus aureus Disease?
- Volume 194, number 12: Human Cytolytic T Cell Recognition of Yersinia pestis Virulence Proteins That Target Innate Immune Responses